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ABSTRACT
Upregulation of Staphylococcal nuclease and tudor domain containing 1 
(SND1) is linked to cancer progression and metastatic spread. Increasing evidence 
indicates that SND1 plays a role in lipid homeostasis. Recently, it has been shown 
that SND1-overexpressing hepatocellular carcinoma cells present an increased 
de novo cholesterol synthesis and cholesteryl ester accumulation. Here we reveal 
that SND1 oncogene is a novel target for SREBPs. Exposure of HepG2 cells to the 
cholesterol-lowering drug simvastatin or to a lipoprotein-deficient medium triggers 
SREBP-2 activation and increases SND1 promoter activity and transcript levels. Similar 
increases in SND1 promoter activity and mRNA are mimicked by overexpressing 
nuclear SREBP-2 through expression vector transfection. Conversely, SREBP-2 
suppression with specific siRNA or the addition of cholesterol/25-hydroxycholesterol 
to cell culture medium reduces transcriptional activity of SND1 promoter and 
SND1 mRNA abundance. Chromatin immunoprecipitation assays and site-directed 
mutagenesis show that SREBP-2 binds to the SND1 proximal promoter in a region 
containing one SRE and one E-box motif which are critical for maximal transcriptional 
activity under basal conditions. SREBP-1, in contrast, binds exclusively to the SRE 
element. Remarkably, while ectopic expression of SREBP-1c or -1a reduces SND1 
promoter activity, knocking-down of SREBP-1 enhances SND1 mRNA and protein 
levels but failed to affect SND1 promoter activity. These findings reveal that SREBP-2 
and SREBP-1 bind to specific sites in SND1 promoter and regulate SND1 transcription 
in opposite ways; it is induced by SREBP-2 activating conditions and repressed by 
SREBP-1 overexpression. We anticipate the contribution of a SREBPs/SND1 pathway 
to lipid metabolism reprogramming of human hepatoma cells.
INTRODUCTION
Staphylococcal nuclease and tudor domain 
containing 1 gene (SND1) encodes the conserved 
multidomain protein SND1, also known as Tudor-
SN, TSN or p100 [1-4]. SND1 has been reported to 
orchestrate multiple functions in the regulation of gene 
expression, including transcriptional activation [5-8], 
spliceosome assembly and pre-mRNA splicing [9, 10], 
RNA interference, stability and editing [11, 12], RNA 
protection in stress granules [13, 14], and regulation 
of protein synthesis, ubiquitination and proteasomal 
degradation [15, 16].
Emerging findings have demonstrated that SND1 
overexpression is linked to progression and malignancy 
of various types of cancer, such as colon, breast, prostate, 
lung, glioma, melanoma and liver cancer [17-23]. These 
studies documented multiple ways for SND1 to facilitate 
carcinogenesis. Participation of SND1 in molecular 
networks involving NF-κB signalling activation and miR-
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221 induction [23], miR-184 expression and JAK/STAT3 
inhibition [21], TGFβ1/Smad signalling pathway [15], 
Wnt/β-catenin activation [17] as well as the interaction 
of SND1 with partner proteins like metadherin-1 [24] 
and monoglyceride lipase [16], have been described to 
strictly modulate prosurvival and proliferative genes and 
proteins expression in cancer cells. The tumour type-
selective oncogenic functions assigned to SND1 may 
be regarded as a result of the ubiquitous expression of 
the protein [25] and its ample capacity for interacting 
with nucleic acids and proteins in the nuclear [26] and 
extranuclear compartments [27-29]. It is in that context 
where our recent studies in human hepatoma HepG2 
cells demonstrated the interaction of nuclear SND1 with 
the genomic DNA and the recruitment of SND1 to the 
promoter of a wide number of target genes modulating 
cell growth, oncogenic transformation, viral infection and 
metabolic regulation [30].
A reprogrammed lipid metabolism and a lipogenic 
phenotype are features that distinguish cancer cells from 
normal cells [31]. Lipids are key metabolic substrates for 
providing energy and building units for the newly forming 
cells; but, they also generate a network of protumorigenic 
signals that promote cancer growth [31]. However, the 
precise mechanisms through which oncogenes alter lipid 
metabolism are yet poorly defined. There is increasing 
evidence indicating that SND1 plays a role in specific 
aspects of lipid bodies biogenesis and the secretion of lipid 
in the milk by mammary epithelial cells [27, 32] or in the 
lipoprotein particles by liver cells [29, 33]. Work from our 
group in knocking-down experiments demonstrated for 
the first time a role for SND1 in the control of expression 
of genes regulating glycerophospholipid homeostasis and 
phosphatidylcholine content during the inflammatory 
response [30]. A very recent insight associated the 
overexpression of SND1 with an enhanced cholesterol 
biosynthesis and storage of cholesteryl esters in rat 
hepatoma cells, suggesting that SND1 may be decisive to 
determine events that modify the permeability properties 
of cancer cell membranes and facilitate cell proliferation 
[34]. Despite all these efforts, the precise function of 
SND1 in managing lipid metabolism in proliferating cells 
and the molecular mechanisms regulating SND1 gene 
expression are important questions that remain to be fully 
understood.
Mammalian sterol regulatory element binding 
proteins (SREBPs) are master regulators of sterol and 
fatty acid homeostasis [35-37]. The three isoforms of 
SREBPs are encoded by two genes: SREBF1 originates 
SREBP-1a and SREBP-1c and a separated gene SREBF2 
encodes SREBP-2. Although significant functional 
overlap between SREBPs exists, SREBP-1c is the main 
responsible for activation of genes involved in fatty acid, 
phospholipid and triacylglycerol synthesis, SREBP-2 
primarily governs cholesterol synthesis and uptake while 
SREBP-1a can regulate both pathways. However, the three 
SREBPs differ in their tissue distribution and responses 
to regulatory challenges. SREBP-1c and SREBP-2 are 
the predominant isoforms expressed in mammalian 
liver although HepG2 and other types of cultured cells 
produced predominantly SREBP-1a and SREBP-2 [38, 
39]. SREBPs are synthesized as inactive precursors 
bound to the endoplasmic reticulum (ER) membrane and 
are subjected to complex posttranslational regulation. 
When the sterol concentration in ER membranes is high, 
SREBPs are retained in the membrane in association 
with SREBP cleavage activating protein (SCAP) and 
insulin induced gene protein (Insig), that are sensitive 
to ER membrane sterol levels. In response to low sterol 
levels, the SCAP/SREBP complex is released from 
Insig and escorted to Golgi where SREBP undergoes 
proteolytic cleavage. The released active amino-terminal 
fragment translocates to the nucleus and binds to sterol 
response elements (SRE) or to palindromic E-boxes and 
transactivates target genes [35, 40]. SREBPs are relatively 
weak activators of transcription, and for maximal action 
they commonly require cooperation with one or more 
accessory transcription factors, most commonly including 
Sp1 (specificity protein 1), NF-Y (nuclear factor Y) or 
both [41].
Our previous studies provided the characterization 
of the human SND1 gene promoter (GenBank ID: 
EF690304). It is a TATA-less promoter containing 
conserved CCAAT and GC boxes for the functional 
binding of NF-Y and Sp1 transcription factors as well as 
several NF-κB binding sites that play a regulatory role in 
the TNFα-induced activation of SND1 transcription [42-
44] and a number of ER stress response elements [45]. 
In addition, the existence of sterol response elements 
within SND1 promoter has been predicted in silico. 
Here we reveal that SREBP-2 and SREBP-1 bind to 
specific sites in the promoter region and regulate SND1 
transcription in opposite ways. Binding sites for SREBPs 
have been analysed in vivo and in vitro and their role 
on SND1 promoter was investigated by determining 
the transcriptional activity of functional and mutated 
5’-deletion fragments. Our findings uncover SND1 as a 
novel target gene for SREBPs that is induced by SREBP-2 
activation upon conditions of sterol depletion in the 
hepatoma cell and repressed by SREBP-1.
RESULTS
Response of SND1 expression to SREBP-2 
activity modulators
To determine whether SND1 expression was 
regulated by SREBP-2, human HepG2 cells were cultured 
under different cellular conditions that modulate SREBP-2 
pathway. Sterol starvation triggers the activation of 
SREBPs pathway and the cleavage of SREBP-2 to the 
active form. Thus, cells were treated with the cholesterol 
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lowering drug simvastatin or were grown in a culture 
medium with lipoprotein deficient serum (LPDS) in 
order to activate SREBP-2. Simvastatin is an inhibitor 
of hydroxymethylglutaryl-coenzyme A reductase 
(HMGCR), the enzyme catalysing the rate limiting step 
in cholesterol biosynthesis, whereby the mevalonate 
pathway is inhibited and the intracellular cholesterol 
levels diminish. We confirmed that HepG2 treatment with 
10 μM simvastatin or the cell culture in LPDS medium 
resulted in the induction of SREBP-2 mRNA and protein 
expression, concomitant with the increase of transcripts 
of downstream target genes HMGCR and LDL receptor 
(LDLR) and unchanged SREBP-1 mRNA content (Figure 
1D and 1E). In parallel, we found that simvastatin or 
LPDS significantly up-regulated (3-fold or 1.6-fold) the 
expression of SND1 mRNA in human hepatoma cells and 
that SND1 protein accumulated in both the nucleus and the 
cytoplasm of simvastatin-treated cells (Figure 1A), though 
it was not significantly altered by LPDS (Figure 1B).
To asses the response of SND1 gene expression to a 
sterol rich condition, HepG2 cells were incubated during 
24 h in the presence of 10 μg/ml cholesterol plus 1 μg/ml 
25-hydroxycholesterol. These sterols bind to SCAP and 
Insig, respectively, impairing the ER-to-Golgi transfer of 
SREBPs and their travelling to the nucleus, thus inhibiting 
SREBP-2 and SREBP-1 pathways. As shown in Figure 
1C, a significant decrease of about 50% was noticed in the 
SND1 transcript level, although SND1 protein remained 
invariable. The transcript level of expression of SREBP-2 
and its target genes was unmodified by sterols (Figure 1D 
and 1E).
Next, we investigated whether the SND1 promoter 
transcriptional activity changed accordingly to the changes 
in SND1 mRNA expression and SREBP-2 activity. 
We assayed HepG2 cells transfected with 5’-deletion 
fragments of the SND1 promoter in the presence or 
absence of simvastatin, LPDS or exogenous sterols. We 
firstly constructed plasmids that contained SND1 promoter 
sequences covering the regions from nucleotide -112 or 
-274 or -416 to +221 (relative to the transcriptional start 
site) ahead from the luciferase coding region into pGL3-
Basic as detailed in previous work [44]. A consistent 
increase in the reporter activity of the SND1 deletion 
fragments was observed in the transfected HepG2 cells 
following exposure to simvastatin (Figure 2A) or LPDS 
medium (Figure 2B). Conversely, exogenous sterols not 
only reduced luciferase activity (Figure 2C, upper panel) 
but also counteracted the LPDS-mediated activation 
of SND1 promoter activity (Figure 2C, lower panel). 
Transfection assays of human embryonic kidney HEK293 
cells, used as a non-hepatic non-tumoral cell line model, 
exhibited similar SND1 promoter activation by simvastatin 
and LPDS, with the exception of the lack of response of 
fragment 416 to simvastatin (Figure 2A and 2B). Also of 
note is the absence of promoter response to exogenous 
sterols in HEK293 cells (Figure 2C). Altogether these 
results are consistent with the concept that there is a 
sterol-sensitive mechanism of transcriptional regulation 
operating for the SND1 gene in human hepatoma cells 
which seems to be somewhat less operative in HEK293 
cells. Both, the activation of the SND1 proximal promoter 
and the upregulation of SND1 expression upon sterol 
deprivation, point to SND1 as a novel SREBP-2 inducible 
gene.
SND1 promoter contains functional binding sites 
for SREBPs
In order to address the binding of SREBP-2 
transcription factor to the SND1 promoter, we first sought 
for potential binding sites within the promoter sequence 
using MatInspector [46] and Jaspar [47] bioinformatics 
tools. Figure 3A shows the sequence of SND1 proximal 
promoter with the predicted sterol response element 
similar to classic SRE and the E-box found by both 
programs at positions -60 and -230 upstream the 
transcription start site, respectively. There are also four 
potential regulatory elements in the distal promoter: two 
SRE motives at -772 and -1092 and two E-box elements 
at -934 and -1237 (Supplementary Figure 1).
We explored the in vitro binding of SREBP-2 and 
SREBP-1 to the SRE -60 and the E-box -230 regulatory 
elements and performed EMSA experiments using nuclear 
extracts from HepG2 cells and digoxigenin-labelled 
oligonucleotides containing the sequences of SRE -60 
(Figure 3B, lanes 1-7) and the canonical E-box -230 site 
(Figure 3B, lanes 8-14) of the SND1 promoter. Figure 
3B shows the formation of two specific DNA-protein 
complexes, one with SRE (lane 3) and one with E-box 
(lane 9) sequence. The specific binding was abolished by 
an excess of the specific unlabelled probe (lanes 4 and 10) 
but not by the non-specific probe for Oct2A (lanes 2 and 
14) or by non-specific IgG (lanes 5 and 11). Although the 
specific bands were not supershifted by anti-SREBP-1 
(lanes 7 and 12) or anti-SREBP-2 (lanes 6 and 13) 
antibodies, we observed that the anti-SREBP-2 IgG and 
not anti-SREBP-1 IgG weakened both the SRE-DNA and 
the E-box-DNA interactions, suggesting SREBP-2 binding 
to the SRE and E-box probes.
Chromatin immunoprecipitation (ChIP) assays were 
performed to verify the binding of endogenous SREBPs 
to the SND1 gene promoter in HepG2 cells. After cross 
linking, chromatin was immunoprecipitated with specific 
antibodies directed against SREBP-2 or SREBP-1 or non-
immune IgG (negative control). Then, the regions (-176, 
+4) and (-268, -73) of SND1 gene promoter containing 
the potential SREBP binding sites were amplified from the 
immunoprecipitates. As Figure 3C shows, both SREBP-1 
and SREBP-2 bound to elements within the promoter 
region (-176, +4) where SRE -60 site is located and a 2.4-
3-fold enrichment for the binding sites was rendered for 
each amplified DNA. Amplification of the region (-268, 
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-73) containing the predicted E-box -230 showed the 
association of SREBP-2 (2.2-fold enrichment) but not of 
SREBP-1 with the regulatory elements in this promoter 
region, revealing that the SREBP-2 and SREBP-1 
transcriptional factors occupy some specific sites in SND1 
proximal promoter.
The functional role of these regulatory elements 
was demonstrated by mutational analysis of the SND1 
Figure 1: SND1 gene transcription responds to SREBP-2 activity modulators. The SND1 transcript level and the SND1 
protein content in nuclei and the cytoplasmic fraction were quantified in control HepG2 cells (white bars) and cells cultured during 24 
h with 10 μM simvastatin (A), or in a lipoprotein deficient (LPDS) medium (B), or in the presence of 10 μg/ml cholesterol plus 1 μg/ml 
25-hydroxycholesterol (Ch/25OHCh) (C) (dark bars). Aliquots of cells (7 x105 cells) were subjected to RNA isolation and first strand cDNA 
was synthesized and used as the template for individual PCR reactions using the primers listed in Supplementary Table 1. Other aliquots (7 
x105 cells) were processed for the isolation of nucleus and cytoplasm and subjected to immunoblot analysis for SND1 and normalized with 
histone H3 and β-tubulin, respectively. The precursor (SREBP-2) and mature SREBP-2 protein content (D) and the HMGCR, LDLR and 
SREBP-1 transcript levels (E) were also determined in cells treated as above, and are expressed relative to the level in control cells, which 
is shown as a grey grid line. Results are reported as the mean ± SD of 3-5 independent experiments, each performed in triplicate (duplicate 
in western blotting), and were analyzed by the two-tailed Student’s t-test. * p≤0.05, ** p≤0.01 and *** p≤0.001 denote the effect of treatment.
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Figure 2: Transcriptional activity of SND1 proximal promoter responds to SREBP-2 activity modulators. SND1 
transcriptional activity was measured in HepG2 and HEK293 cells (10 x103) transiently transfected with SND1 promoter constructs p112, 
p274 or p416 covering the promoter sequence (-112, +221) or (-274, +221) or (-416, +221) cloned in pGL3-Basic vector as described in 
Material and methods and cultured during 24 h with 10 μM simvastatin (A), or in a lipoprotein deficient (LPDS) medium (B), or in the 
presence of 10 μg/ml cholesterol plus 1 μg/ml 25-hydroxycholesterol (Ch/25OHCh) (C) (dark bars). Promoter activity is represented 
as luciferase arbitrary units relative to its corresponding control, untreated p112 fragment. Results are reported as the mean ± SD of 3-5 
independent experiments, each performed in quadruplicate and were analyzed by the two-tailed Student’s t-test. ** p≤0.01 and *** p≤0.001 
denote the effect of treatment, ###p≤0.001 denotes the effect of Ch/25OHCh+LPDS versus LPDS alone.
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promoter. Site-directed mutagenesis to the core sequence 
for the SRE -60 or the E-box -230 motif was performed 
in the 5’-deletion fragments p112 and p274. The reporter 
constructs carrying the individual SRE or E-box mutations 
rendered a reduced luciferase activity (40-70%) respect to 
that measured in the wild-type constructs in HepG2 cells 
(Figure 3D). A more dramatic inhibition (80-90%) in the 
luciferase activity of mutated fragments was measured 
in HEK293 cells (Figure 3D). Such reductions in 
transcriptional activity strongly suggest that these SREBP 
binding sites are regulatory elements for the promoter 
function and transcription of the human SND1 gene.
Figure 3: SND1 promoter contains functional binding sites for SREBPs. (A) Partial nucleotide sequence of SND1 gene proximal 
promoter [GenBank: EF690304]. The transcription start site (+1) is shown in bold. Boxes indicate predicted binding motives for SREBP 
transcription factors SRE -60 and E-box -230. (B) Electrophoretic mobility shift assay for the predicted SRE and E-box sequences using 
HepG2 nuclear extracts. Competition assays were performed with 100x excess of specific or non-specific unlabelled probe. Lanes 1 and 8 
free probe, lanes 3 and 9 HepG2 nuclear extracts, lanes 2 and 14 non-specific competitor, lanes 4 and 10 SRE -60 and E-box -230 specific 
competitor, respectively, lanes 5 and 11 non-specific antibodies, lanes 6 and 13 anti-SREBP-2 IgG, and lanes 7 and 12 anti-SREBP-1 IgG. 
(C) Binding of endogenous SREBP-1 and SREBP-2 to SND1 gene promoter. Chromatin from HepG2 cells was immunoprecipitated with 
anti-SREBP-2, anti-SREBP-1, or non-immune IgG as negative control. DNA from input or immunoprecipitates (IP) was subjected to PCR 
to amplify SND1 promoter (-268, -73) and (-176, +4) regions containing the predicted SRE or E-box elements. Results in B and C are 
representative of three experiments with similar results. (D) Site-directed mutagenesis for SRE -60 or E-box -230 motif was performed 
in HepG2 and HEK293 cells as described in Material and methods and SND1 promoter activity measured and expressed relative to non-
mutated p112 luciferase activity. Results are reported as the mean ± SD of 3 independent experiments, each performed in quadruplicate, 
and were analyzed by the two-tailed Student’s t-test. Significance is denoted: *** p≤0.001.
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SND1 expression positively correlates with the 
expression level of SREBP-2
In order to delineate the regulatory role of SREBPs 
on SND1 gene expression, we performed gain-of-function 
and loss-of function experiments. Transient cotransfection 
of HepG2 cells with SND1 promoter constructs plus 
human SREBP-2 or SREBP-1a or -1c expression plasmids 
were carried out. Cotransfected cells displayed a very 
efficient mRNA overexpression of SREBP-2 (80-fold) 
(Figure 4A) and SREBP-1a (50-fold) and a more modest 
increase in the SREBP-1c mRNA (2-fold) (Figure 4C). In 
general, a less strong effect on the corresponding mature 
protein (2-8 fold) was detected by Western blotting 
(Figure 4A and 4C). SREBP-2 overexpression resulted 
in significant activation of SND1 promoter activity, 
which was accompanied by a rise in SND1 mRNA and 
protein (Figure 4B), the latter being mainly accumulated 
in the nucleus (data not shown). On the contrary, and 
remarkably, cells overexpressing SREBP-1a or SREBP-1c 
displayed a marked decrease in the SND1 transcriptional 
activity and no alterations in SND1 transcript and 
protein amount (Figure 4D). Such contrasting effects of 
SREBP-2 and SREBP-1a and -1c on SND1 gene promoter 
transcriptional rate point to a dual regulatory mechanism 
for SND1 expression in hepatoma cells.
Next, we evaluated SND1 gene expression in 
HepG2 cells with siRNA-mediated depletion of SREBP-2 
or SREBP-1. The deletion was induced by transfecting 
cells with siRNAs directed against regions 1193-1211 
or 1566-1584 of SREBP-2 mRNA or regions 505-523 
or 4044-4062 of SREBP-1 transcript. The silencing of 
each SREBP was successful as evidenced by the residual 
amount of SREBP-2 and SREBP-1 mRNA and the reduced 
nuclear protein detected in the siRNA-transfected cells 
compared to the mock-transfected cells (Supplementary 
Figures 2 and 3). No cross-reactions between the siRNAs 
for SREBP-1 and SREBP-2 transcript were confirmed, 
but we discarded the SREBP-2 siRNA matching region 
1193-1211 because it cross-reacted with SREBP-1 gene 
and reduced by about 50% the expression of SREBP-1 
transcript. Ten nM siRNAs and 48 h were defined as 
optimal parameters for HepG2 cells considering the 
maximal inhibition of the SREBP-2 target gene HMGCR 
transcript and the marked decrease in free and esterified 
cholesterol content (Supplementary Figure 2C and 2D), 
and the impaired HepG2 cell proliferation due to SREBP-2 
deletion from 48 h ahead (Supplementary Figure 2E). 
Inhibition of endogenous SREBP-2 by siRNA reduced 
the activity of SND1 promoter and the expression of 
SND1 mRNA and protein (Figure 5). However, SREBP-1 
silencing did not affect luciferase activity of the SND1 
5’-deletion fragments although it augmented the level of 
expression of SND1 transcript and protein (Figure 5).
Collectively, these findings evidence that SND1 
transcription is controlled by SREBPs and the binding of 
SREBP-2 and/or SREBP-1 to specific sites in the gene 
promoter might ensue opposite responses of SND1 gene 
expression, at least in the hepatic HepG2 cell context.
DISCUSSION
Here we attempt to decipher the transcriptional 
control of SND1 gene by SREBP-2 and SREBP-1 
transcription factors in human hepatoma cells. The 
first novel result in the present study is a neat SREBP-
2-mediated activation of SND1 expression under 
cholesterol-lowering conditions. This is the classic model 
of regulation of SREBPs activity by intracellular sterol 
concentration that fits well with SREBP-2. Lipoprotein 
deficiency or simvastatin treatment activated SREBP-2 
and raised SND1 promoter activity and mRNA abundance 
while the addition of sterols to the culture medium 
decreased SND1 promoter activity and mRNA expression. 
The mixture of cholesterol and 25-hydroxycholesterol 
seemed to be insufficient to affect the regulatory pool of 
cholesterol and did not produce consistent reduction in 
SREBP-2 transcript and nuclear protein (Figures 1 and 2). 
However, taking into account that 25-hydroxycholesterol 
belongs to a large family of oxysterols that can bind 
different nuclear receptors, such as liver X receptor 
(LXR), and/or other regulatory proteins [48, 49] and 
may serve as important modulator of the expression of 
multiple genes, it is tempting to speculate that SND1 
could be included among them. The SREBP-2 gain-of-
function and loss-of function experiments reinforced the 
positive connection between SND1 promoter activity 
and transcript expression, and SREBP-2 activity (Figures 
4 and 5). Moreover, ChIP assays confirmed the binding 
of endogenous SREBP-2 to two SND1 promoter regions 
exhibiting recognition domains, SRE -60 and E-box -230, 
and mutational analysis demonstrated the functional role 
for these two binding sites in the positive regulation of the 
human SND1 promoter activity by SREBP-2 transcription 
factor (Figure 3). A similar regulatory mechanism seems 
to operate over SND1 promoter in HEK293 cells with a 
few divergences in the responsiveness to sterol (Figures 
2 and 3) that may be attributed to a different network of 
transcription factors operating in these non-hepatic, non-
tumoral cells compared to HepG2 cells.
Our study also reveals that endogenous SREBP-1 
occupies a specific site in the promoter region containing 
the regulatory element SRE -60, and that, SREBP-1a or 
SREBP-1c overexpression led to an unexpected reduction 
in the transcriptional activity of SND1 promoter that did 
not affect the level of SND1 transcript (Figure 4). It is 
interesting to mention that knocking down SREBP-1 
released SND1 promoter from the SREBP-1 repressive 
action and raised the cellular amount of SND1 mRNA and 
protein. This observation leads us to suggest that SREBP-1 
either serve as an SND1 promoter inhibitor or affect other 
posttranscriptional processes regulating SND1 expression.
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Figure 4: SND1 gene transcription is dependent on the cellular SREBP levels. HepG2 cells were transfected with expression 
plasmids of human SREBP-2 (A and B) or SREBP-1a or SREBP-1c (C and D). After 24h, (A and C) SREBPs and (B and D) SND1 
transcript and protein levels and SND1 gene promoter activity were determined as described in Material and methods. Transcript and 
protein levels are expressed relative to the level in control cells. Promoter activity is expressed as luciferase arbitrary units relative to 
its corresponding p112 control. Results are reported as the mean ± SD of 3 independent experiments, each performed in quadruplicate 
(triplicate or duplicate in western blotting), and were analyzed by the two-tailed Student’s t-test. Significance is denoted: * p≤0.05, ** p≤0.01 
and *** p≤0.001 versus control cells.
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Opposite effects of SREBPs have been described 
for a few genes [50]. In light of our findings, we can 
speculate that SREBP-2 or SREBP-1 isoforms bind the 
SRE -60 site in SND1 promoter activating or inactivating 
its transcriptional activity in response to upstream signals 
and the set of transcription factors and cofactors recruited 
to the gene promoter. Overlapping between SREBP-2 
and SREBP-1 target genes has been previously reported 
in liver cells even though each isoform appears to bind 
to different set of targets depending on the particular 
cellular environment [53, 54] and the structure of the 
gene promoter [39]. Differential transactivity of SREBP-
1a, -1c and -2 on SREBP-target promoters is defined 
by the position of their SRE and E-box motifs and the 
requirement of other transcription factors as cofactors for 
the SREBPs activation. It is well established that SREBPs 
usually cooperate with transcription factors such as Sp1 
and NF-Y to exert their regulatory effects on their target 
genes [41, 55] and that nucleotide spacing length between 
the SRE and NF-Y or Sp1 binding sites is decisive for 
optimal sterol-dependent transcriptional regulation [55]. 
The SND1 gene promoter contains conserved Sp1 and 
NF-Y sites that are located close to or even overlap the 
SREBPs recognition domain SRE -60 [44]. Preliminary 
findings point to that SREBP-2-mediated stimulation of 
SND1 promoter activity is independent on the binding 
of Sp1 and/or NF-Y to the promoter and a combination 
with NF-Y is required for the efficient inhibition of SND1 
promoter activity by SREBP-1 (Supplementary Figure 
4). We have to keep in mind that both several upstream 
SRE and/or E-box elements in the distal promoter 
(Supplementary Figure 1) and the regulatory network of 
proteins interacting with the SND1 promoter sequence 
(Supplementary Figure 5) could play relevant roles in 
the regulation of SND1 gene expression by SREBPs. 
Because of the complex networks that control SREBPs 
functions [37, 51, 52], further studies should be carried out 
to understand the precise molecular mechanism and the 
combination of transcription factors required in the control 
of SND1 promoter by SREBP transcription factors.
Besides the transcriptional control of SND1 gene, 
other alternative effects of SREBPs may occur at the 
postranscriptional level and affect the SND1 mRNA 
processing and the formation of the protein. Both SREBF2 
and SREBF1 encode microRNAs, miR-33a and miR-
33b respectively, and the coordinate expression of the 
corresponding SREBP/miRNA represents a mechanism 
to regulate the expression of the genes responsible of 
cholesterol homeostasis maintenance [56]. Whether SND1 
gene might be included within this group is an intriguing 
hypothesis to be evaluated. Up to date, the limited 
information relative to the postranscriptional regulation 
of SND1 identifies SND1 transcript as a target of miR-
184 in malignant gliomas and breast cancer [21, 57] and 
miR-361-5p in colorectal and gastric cancer [58] and links 
miRNAs suppression with SND1 upregulation and cancer 
development and progression.
Our findings here reported about the SREBP-2-
mediated activation of SND1 transcription in response 
to sterol-lowering treatments are consistent with a recent 
study in rat hepatoma cells overexpressing SND1 that 
evidence a constitutive overactivation of the SREBP-2 
regulatory system [34]. The authors documented that 
SND1 overexpression deregulated cholesterol metabolism 
and increased the content of free and esterified cholesterol; 
despite the high intracellular cholesterol level, regulatory 
Figure 5: SREBP-1 or SREBP-2 depletion affects SND1 gene transcription. For knocking-down assays, reverse transfection 
was performed with 10 nM specific siRNAs for SREBP-1 or SREBP-2, and SND1 mRNA, protein and luciferase activity were determined 
in HepG2 cells expressing either basal (white bars) or residual levels of SREBPs after silencing endogenous SREBP-1 (light grey) or 
SREBP-2 (dark grey). Transcript and protein levels are expressed relative to the level in control cells. Silencing efficiency was monitored 
through the residual SND1 protein detected after 10 nM siSND1 transfection, and promoter activity is expressed as luciferase arbitrary units 
relative to its corresponding p112 control. Results are reported as the mean ± SD of 3 independent experiments, each performed in triplicate 
(duplicate in western blotting), and were analyzed by the two-tailed Student’s t-test. Significance is denoted: * p≤0.05 and ** p≤0.01 versus 
control cells.
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cholesterol pools in the ER membranes were altered 
and SREBP-2 proteolytic activation was favoured [34]. 
We assume as a hypothesis a regulatory feed-forward 
loop between SREBP-2 and SND1 transcription and 
consequently, the overexpression of SND1 may disrupt 
cholesterol homeostasis and activate the SREBP-2 
pathway in the hepatic cancer cells.
In summary, this study provides first evidence to 
support that human SND1 oncogene is under the control 
of SREBP-2 and SREBP-1 and points to a novel SREBPs/
SND1 pathway that highlights the necessity for defining 
their upstream modulating signals and their downstream 
effector molecules to better understand the relative 
contribution of SND1 to lipid metabolism in liver cancer 
cells.
MATERIALS AND METHODS
Cell culture and treatments
Human hepatocellular carcinoma HepG2 cells 
(ATCC) and human embryonic kidney HEK293 cells 
(ATCC) were grown in EMEM (ATCC) supplemented 
with 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/
ml streptomycin (Sigma-Aldrich) and 10% (v/v) foetal 
bovine serum (ATCC) at 37ºC and 5% CO2. In some 
experiments foetal bovine serum was replaced by 10% 
lipoprotein deficient serum (LPDS) (Sigma). For RNA or 
protein determination 7x105 cells were seeded in 6 well 
plates; and for measurement of SND1 transcriptional 
activity 10x103 cells/well in 96 well plates were used. 
When indicated, cells were treated for 24 h with 10 μM 
simvastatin or with a mixture of 10 μg/ml cholesterol plus 
1 μg/ml 25-hydroxycholesterol; same volume of solvent, 
DMSO or ethanol respectively, was added to control cells.
Transient transfection and luciferase reported 
assay
HepG2 cells were transiently transfected with 0.1 μg 
SND1 constructs p112, p274 and p416, which cover the 
promoter regions (-112, +221), (-274, +221) and (-416, 
+221) cloned into the Firefly luciferase reporter vector 
pGL3-Basic (Promega) and 0.1 μg of Renilla luciferase 
pRL-TK (Promega), using XTreme9 transfection reagent 
(Roche Applied Science) as described in [44]. Mutants of 
constructs p112 and p274 containing mutations in SRE 
(TctaCCatcaG, the underlined sequences indicate the 
mutated nucleotides) or E-box (CTccgtgaTCC) element 
were cloned into the Firefly luciferase vector pRP 
(VectorBuilder, Cyagen Biosciences). HEK293 cells were 
transfected with 0.05 μg reporter gene constructs plus 
0.05 μg Renilla luciferase. After 24 h, cells were lysed 
and luciferase activity was determined in quadruplicate 
from promoter constructs by the Dual-Luciferase Reporter 
Assay System (Promega). Firefly luciferase activity was 
normalized to Renilla luciferase. Luciferase data were 
expressed as relative luminescence units (RLU), setting to 
1.0 the value for p112 fragment.
In the transactivation experiments cells were 
cotransfected with 0.1 μg pcDNA3-SREBP-1a plasmid 
(gift from Timothy Osborne, Addgene plasmid # 26801) 
or pSVSport-SREBP-1c plasmid (gift from Bruce 
Spiegelman, Addgene plasmid # 26807) or pcDNA3-
SREBP-2 (gift from Timothy Osborne, Addgene plasmid 
# 8883). As negative controls the empty pCDNA3 vector 
or the pSVSport SREBP-1c dom neg, which expresses a 
non-functional mature form of SREBP-1c substituying 
Tyr-320 by Ala (gift from Bruce Spiegelman, Addgene 
plasmid # 8885), were used. In these experiments pSV-
β-Galactosidase was used for controlling transfection 
efficiency and Firefly luciferase activity was normalized 
to galactosidase activity.
Determination of mRNA levels
Total RNA was extracted from HepG2 cells using 
TRIzol (Invitrogen Life Technologies), quantified using 
a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies) and the RNA purity was determined by the 
A260/A280 ratio (all samples >1.8). Transcript levels were 
measured by quantitative real-time PCR. First-strand cDNA 
was synthesized from 1 μg RNA using the SuperScript 
III system (Invitrogen) and PCR analysis was conducted 
by the SYBR Green method on the ABI 7000 Sequence 
Detection System (Applied Biosystems). The relative 
amounts of mRNA were calculated from the Ct data applying 
calibration curves and normalized with hypoxanthine 
phosphoribosyltransferase (HRPT), TATA box binding protein 
(TBP) and hydroxymethylbilane synthase (HMBS) using 
GeNorm 3.5 software as described in [59]. Oligonucleotides 
used for qPCR are listed in Supplementary Table 1.
Western blotting
The level of SND1, SREBP-2 and SREBP-1 protein 
was determined by Western blot analysis in the whole 
lysates and in the nuclear and cytoplasmic fractions of 
control and treated HepG2 cells. Cells were lysed and the 
nuclear and cytoplasmic fractions were separated using 
a Nuclear Extraction Kit (Panomics), according to the 
manufacturer’s indications as described in [30]. Protein 
concentrations were determined using a commercially 
available kit (Bio-Rad). Ten micrograms of protein were 
loaded in each lane, fractionated on 9% SDS-PAGE at 170 
V for 1 h and transferred to PVDF membranes (Bio-Rad) 
by semi-dry transference (1 h at 20 V). SND1, SREBP-2 
and SREBP-1 were detected by immunoblotting using 
rabbit anti-SND1 [33], rabbit anti-SREBP-1 (H-160 Santa 
Cruz Biotechonolgy) and mouse anti-SREBP-2 (1C6 Santa 
Cruz Biotechonolgy) antibodies (0.3 μg/ml) respectively. 
Normalization was performed with β-tubulin (cytoplasm) 
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or histone H3 (nucleus), using mouse anti-β-tubulin (Santa 
Cruz Biotechnology) and mouse anti-H3 (Cell Signaling 
Technology) primary antibodies. Horseradish peroxidase-
conjugated goat anti-rabbit IgG (Sigma-Aldrich), and 
horse anti-mouse IgG (Sigma-Aldrich) were used as 
secondary antibodies. Detection was performed by ECL 
(GE Healthcare Life Sciences) and quantification by 
optical densitometry using QuantityOne software (Bio-
Rad). Results are expressed as fold-change relative to the 
corresponding protein level in control cells.
Electrophoretic mobility shift assays (EMSA)
Bicatenary DNA probes corresponding to SRE -60 
(5’CAGGGTGCCTATTGGCCTGAGGGCCGGCGGG3’) 
and E-box -230 (5’GGCCAGATGCTGACGTGTCCTTT
CCTTCC3’) sequences within SND1 proximal promoter 
were labelled with digoxigenin using the DIG Gel shift kit 
2nd Generation (Roche Applied Science). For mobility shift 
assays, 1-2 μg nuclear extracts protein from HepG2 cells were 
incubated for 15 min at room temperature with 0.8 ng (0.04 
pmol) of the labelled probes. For specific and non-specific 
competition assays, 100-fold molar excess of unlabelled 
probe was used. For supershift assays, 1 μg anti-SREBP-1 
antibody or anti-SREBP-2 (Santa Cruz Biotechnology) 
or unspecific IgG was added. Electrophoresis, blotting, 
crosslinking and chemiluminescent detection were performed 
as described elsewhere [42].
Chromatin immunoprecipitation (ChIP) assays
Chromatin Immunoprecipitation assays were 
performed using the EpiTectChIP One-Day Kit 
(SABiosciences) following manufacturer’s instructions as 
described in [30]. The chromatin was immunoprecipitated 
with anti-SREBP-1 (H-160, Santa Cruz Biotechnology), 
anti-SREBP-2, (N-19 Santa Cruz Biotechnology) or 
non-immune serum IgG as negative control. DNA 
samples from immunoprecipitated (IP) material and 
from input were analysed by qPCR using the primers 
given in Supplementary Table 2. SYBR Green method 
was performed using 2-4 μl of the IP or input samples 
as templates and 0.1 μM specific primers. Results are 
given as the enrichment of the IP relative to the negative 
control and determined as 2-(ΔΔCt) being ΔΔCt=(Ct(IP)-
Ct(input)) – (Ct(IgG)-Ct(input)). Conventional PCR analyses 
were performed with 2 μl of immunoprecipitates or input 
samples and 0.4 μM specific primers under the following 
conditions: 94°C for 3 min; 35 cycles at 94°C for 20 sec, 
59°C for 30 sec, and 72°C for 30 sec; and final extension 
at 72°C for 2 min. The samples were analysed on a 3% 
(w/v) agarose gel.
Small interfering RNA (siRNA) gene silencing
For silencing endogenous SREBP-1 and SREBP-2, 
HepG2 cells were reverse transfected with 10 nM or 30 nM 
pre-designed siRNA against human SREBP-1 (Forward 
505-523: CCACUCCAUUGAAGAUGUA, reverse 505-
523: UACAUCUUCAAUGGAGUGG and forward 4044-
4062: GGAGAGAGACGUGUACAUA, reverse 4044-
4062: UAUGUACACGUCUCUCUCC) or SREBP-2 
(Forward 1193-1211: CCCAUAAUAUCAUUGAGAA, 
reverse 1193-1211: UUCUCAAUGAUAUUAUGGG and 
forward 1566-1584: GGAUGAUGCAAAGGUCAAA, 
reverse 1566-1584: UUUGACCUUUGCAUCAUCC), or 
Silencer® negative control siRNA using Lipofectamine 
RNAiMAX transfection reagent according to 
the manufacturer´s instructions (Invitrogen Life 
Technologies). The knocking-down efficiency was 
checked by measuring target gene transcript by RT-qPCR 
and immunoblotting. After 48 or 72 h, cells were lysed 
with TRIzol for RNA analysis, or with lysis buffer for 
protein analysis. For SND1 transcriptional activity assay, 
after 48 h silencing, culture medium was replaced with 
fresh medium, cells were transfected for 24 h with SND1 
gene promoter constructs and luciferase activity was 
measured as described above.
Statistical analysis
The results are shown as the mean ± SD of at least 
3 independent experiments, each performed in triplicate, 
except otherwise stated. Statistical significance of results 
was assessed by the unpaired Student’s t-test using 
GraphPad Prism (version 5; GraphPad Software Inc., CA).
Abbreviations
ChIP, chromatin immunoprecipitation; DMSO, 
dimethyl sulfoxide; EMSA, electrophoretic mobility 
shift assays; ER, endoplasmic reticulum; HMGCR, 
hydroxymethylglutaryl-coenzyme A reductase; IP, 
immunoprecipitated; LDLR, low density lipoprotein 
receptor; LPDS, lipoprotein deficient serum; LXR, liver X 
receptor; NF-Y, nuclear factor Y; SCAP, SREBP cleavage 
activating protein; SND1, staphylococcal nuclease 
domain-containing protein 1; Sp1, specificity protein 1; 
SREBP, sterol regulatory element (SRE) binding protein.
Author contributions
SA carried out the promoter assays, EMSA, 
chromatin immunoprecipitation analysis and participated 
in the interpretation of data. EA participated in the binding 
validation assays and in the immunoblotting analysis. LE 
carried out the RNA extraction and participated in the 
quantitative real-time PCR analysis. IL performed the 
small interfering RNA gene silencing. HNI participated in 
the experiments with the HEK293 cells. UM contributed 
specific immunoblotting analysis. BO revised critically 
and edited the manuscript. YC participated in the design 
of the study and performed the statistical analysis and 
drafted the manuscript. MJM conceived and designed 
Oncotarget108192www.impactjournals.com/oncotarget
the study, and participated in its coordination, and wrote 
the manuscript. All authors read and approved the final 
manuscript.
ACKNOWLEDGMENTS
The authors thank Mr. José Antonio López for his 
technical help with cell cultures. Technical and human 
support provided by SGIker (UPV/EHU, MICINN, GV/
EJ, ERDF and ESF) is gratefully acknowledged.
CONFLICTS OF INTEREST
The authors declare that they have no conflicts of 
interest.
FUNDING
This study was supported by Gobierno Vasco grants 
[IT971-16 and KK2016-00036] and UPV/EHU [UFI11/20 
CLUMBER]. S.A., E.A. and H.N.I. were recipients of 
grants from UPV/EHU and Gobierno Vasco.
REFERENCES
1. Hossain MJ, Korde R, Singh PK, Kanodia S, Ranjan R, 
Ram G, Kalsey GS, Singh R, Malhotra P. Plasmodium 
falciparum Tudor Staphylococcal Nuclease interacting 
proteins suggest its role in nuclear as well as splicing 
processes. Gene. 2010; 468:48-57.
2. Frey dit NF, Muller P, Jammes F, Kizis D, Leung J, Perrot-
Rechenmann C, Bianchi MW. The RNA binding protein 
Tudor-SN is essential for stress tolerance and stabilizes 
levels of stress-responsive mRNAs encoding secreted 
proteins in Arabidopsis. Plant Cell. 2010; 22:1575-1591.
3. Zhao CT, Shi KH, Su Y, Liang LY, Yan Y, Postlethwait J, 
Meng AM. Two variants of zebrafish p100 are expressed 
during embryogenesis and regulated by nodal signaling. 
FEBS Lett. 2003; 543:190-195.
4. Broadhurst MK, Wheeler TT. The p100 coactivator is 
present in the nuclei of mammary epithelial cells and its 
abundance is increased in response to prolactin in culture 
and in mammary tissue during lactation. J Endocrinol. 
2001; 171:329-337.
5. Leverson JD, Koskinen PJ, Orrico FC, Rainio EM, Jalkanen 
KJ, Dash AB, Eisenman RN, Ness SA. Pim-1 kinase and 
p100 cooperate to enhance c-Myb activity. Mol Cell. 1998; 
2:417-425.
6. Paukku K, Yang J, Silvennoinen O. Tudor and nuclease-like 
domains containing protein p100 function as coactivators 
for signal transducer and activator of transcription 5. Mol 
Endocrinol. 2003; 17:1805-1814.
7. Yang J, Aittomaki S, Pesu M, Carter K, Saarinen J, 
Kalkkinen N, Kieff E, Silvennoinen O. Identification of 
p100 as a coactivator for STAT6 that bridges STAT6 with 
RNA polymerase II. EMBO J. 2002; 21:4950-4958.
8. Duan Z, Zhao X, Fu X, Su C, Xin L, Saarikettu J, Yang X, 
Yao Z, Silvennoinen O, Wei M, Yang J. Tudor-SN, a novel 
coactivator of peroxisome proliferator-activated receptor 
gamma protein, is essential for adipogenesis. J Biol Chem. 
2014; 289:8364-8374.
9. Yang J, Valineva T, Hong J, Bu T, Yao Z, Jensen ON, 
Frilander MJ, Silvennoinen O. Transcriptional co-activator 
protein p100 interacts with snRNP proteins and facilitates 
the assembly of the spliceosome. Nucleic Acids Res. 2007; 
35:4485-4494.
10. Gao X, Zhao X, Zhu Y, He J, Shao J, Su C, Zhang Y, Zhang 
W, Saarikettu J, Silvennoinen O, Yao Z, Yang J. Tudor 
staphylococcal nuclease (Tudor-SN; participates in small 
ribonucleoprotein (snRNP) assembly via interacting with 
symmetrically dimethylated Sm proteins. J Biol Chem. 
2012; 287:18130-18141.
11. Caudy AA, Ketting RF, Hammond SM, Denli AM, 
Bathoorn AM, Tops BB, Silva JM, Myers MM, Hannon GJ, 
Plasterk RH. A micrococcal nuclease homologue in RNAi 
effector complexes. Nature. 2003; 425:411-414.
12. Li CL, Yang WZ, Chen YP, Yuan HS. Structural and 
functional insights into human Tudor-SN, a key component 
linking RNA interference and editing. Nucleic Acids Res. 
2008; 36:3579-3589.
13. Gao X, Ge L, Shao J, Su C, Zhao H, Saarikettu J, Yao X, 
Yao Z, Silvennoinen O, Yang J. Tudor-SN interacts with 
and co-localizes with G3BP in stress granules under stress 
conditions. FEBS Lett. 2010; 584:3525-3532.
14. Weissbach R, Scadden AD. Tudor-SN and ADAR1 are 
components of cytoplasmic stress granules. RNA. 2012; 
18:462-471.
15. Yu L, Liu X, Cui K, Di Y, Xin L, Sun X, Zhang W, Yang 
X, Wei M, Yao Z, Yang J. SND1 acts downstream of 
TGFbeta1 and upstream of Smurf1 to promote breast cancer 
metastasis. Cancer Res. 2015; 75:1275-1286.
16. Rajasekaran D, Jariwala N, Mendoza RG, Robertson 
CL, Akiel MA, Dozmorov M, Fisher PB, Sarkar D. 
Staphylococcal nuclease and tudor domain containing 
1 (SND1 Protein) promotes hepatocarcinogenesis by 
inhibiting monoglyceride lipase (MGLL). J Biol Chem. 
2016; 291:10736-10746.
17. Tsuchiya N, Ochiai M, Nakashima K, Ubagai T, Sugimura 
T, Nakagama H. SND1, a component of RNA-induced 
silencing complex, is up-regulated in human colon cancers 
and implicated in early stage colon carcinogenesis. Cancer 
Res. 2007; 67:9568-9576.
18. Ho J, Kong JW, Choong LY, Loh MC, Toy W, Chong PK, 
Wong CH, Wong CY, Shah N, Lim YP. Novel breast cancer 
metastasis-associated proteins. J Proteome Res. 2009; 
8:583-594.
19. Kuruma H, Kamata Y, Takahashi H, Igarashi K, Kimura 
T, Miki K, Miki J, Sasaki H, Hayashi N, Egawa S. 
Oncotarget108193www.impactjournals.com/oncotarget
Staphylococcal nuclease domain-containing protein 1 as 
a potential tissue marker for prostate cancer. Am J Pathol. 
2009; 174:2044-2050.
20. Zagryazhskaya A, Surova O, Akbar NS, Allavena 
G, Gyuraszova K, Zborovskaya IB, Tchevkina EM, 
Zhivotovsky B. Tudor staphylococcal nuclease drives 
chemoresistance of non-small cell lung carcinoma cells by 
regulating S100A11. Oncotarget. 2015; 6: 12156-12173. 
https://doi.org/10.18632/oncotarget.3495.
21. Emdad L, Janjic A, Alzubi MA, Hu B, Santhekadur PK, 
Menezes ME, Shen XN, Das SK, Sarkar D, Fisher PB. 
Suppression of miR-184 in malignant gliomas upregulates 
SND1 and promotes tumor aggressiveness. Neuro Oncol. 
2015; 17:419-429.
22. Sand M, Skrygan M, Georgas D, Sand D, Gambichler T, 
Altmeyer P, Bechara FG. The miRNA machinery in primary 
cutaneous malignant melanoma, cutaneous malignant 
melanoma metastases and benign melanocytic nevi. Cell 
Tissue Res. 2012; 350:119-126.
23. Santhekadur PK, Das SK, Gredler R, Chen D, Srivastava 
J, Robertson C, Baldwin AS, Fisher PB Jr, Sarkar D. 
Multifunction protein staphylococcal nuclease domain 
containing 1 (SND1) promotes tumor angiogenesis in 
human hepatocellular carcinoma through novel pathway 
that involves nuclear factor kappaB and miR-221. J Biol 
Chem. 2012; 287:13952-13958.
24. Yoo BK, Santhekadur PK, Gredler R, Chen D, Emdad L, 
Bhutia S, Pannell L, Fisher PB, Sarkar D. Increased RNA-
induced silencing complex (RISC) activity contributes to 
hepatocellular carcinoma. Hepatology. 2011; 53:1538-1548.
25. Fashe T, Saarikettu J, Isomaki P, Yang J, Silvennoinen O. 
Expression analysis of Tudor-SN protein in mouse tissues. 
Tissue Cell. 2013; 45:21-31.
26. Valineva T, Yang J, Palovuori R, Silvennoinen O. The 
transcriptional co-activator protein p100 recruits histone 
acetyltransferase activity to STAT6 and mediates interaction 
between the CREB-binding protein and STAT6. J Biol 
Chem. 2005; 280:14989-14996.
27. Keenan TW, Winter S, Rackwitz HR, Heid HW. Nuclear 
coactivator protein p100 is present in endoplasmic reticulum 
and lipid droplets of milk secreting cells. Biochim Biophys 
Acta. 2000; 1523:84-90.
28. Fresnedo O, López de Heredia M, Martinez MJ, Cristobal 
S, Rejas MT, Cuezva JM, Ochoa B. Immunolocalization 
of a novel cholesteryl ester hydrolase in the endoplasmic 
reticulum of murine and human hepatocytes. Hepatology. 
2001; 33:662-667.
29. Garcia-Arcos I, Rueda Y, Gonzalez-Kother P, Palacios L, 
Ochoa B, Fresnedo O. Association of SND1 protein to low 
density lipid droplets in liver steatosis. J Physiol Biochem. 
2010; 66:73-83.
30. Arretxe E, Armengol S, Mula S, Chico Y, Ochoa B, 
Martinez MJ. Profiling of promoter occupancy by the 
SND1 transcriptional coactivator identifies downstream 
glycerolipid metabolic genes involved in TNFalpha 
response in human hepatoma cells. Nucleic Acids Res. 
2015; 43:10673-10688.
31. Currie E, Schulze A, Zechner R, Walther TC, Farese RV 
Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 
2013; 18:153-161.
32. Ao J, Wei C, Si Y, Luo C, Lv W, Lin Y, Cui Y, Gao X. 
Tudor-SN regulates milk synthesis and proliferation of 
bovine mammary epithelial cells. Int J Mol Sci. 2015; 
16:29936-29947.
33. Palacios L, Ochoa B, Gomez-Lechon MJ, Castell JV, 
Fresnedo O. Overexpression of SND p102, a rat homologue 
of p100 coactivator, promotes the secretion of lipoprotein 
phospholipids in primary hepatocytes. Biochim Biophys 
Acta. 2006; 1761:698-708.
34. Navarro-Imaz H, Rueda Y, Fresnedo O. SND1 
overexpression deregulates cholesterol homeostasis in 
hepatocellular carcinoma. Biochim Biophys Acta. 2016; 
1861:988-996.
35. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein 
sensors for membrane sterols. Cell. 2006; 124:35-46.
36. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of 
the complete program of cholesterol and fatty acid synthesis 
in the liver. J Clin Invest. 2002; 109:1125-1131.
37. Jeon TI, Osborne TF. SREBPs: metabolic integrators in 
physiology and metabolism. Trends Endocrinol Metab. 
2012; 23:65-72.
38. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown 
MS. Differential expression of exons 1a and 1c in mRNAs 
for sterol regulatory element binding protein-1 in human 
and mouse organs and cultured cells. J Clin Invest. 1997; 
99:838-845.
39. Amemiya-Kudo M, Shimano H, Hasty AH, Yahagi 
N, Yoshikawa T, Matsuzaka T, Okazaki H, Tamura Y, 
Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, et al. 
Transcriptional activities of nuclear SREBP-1a, -1c, 
and -2 to different target promoters of lipogenic and 
cholesterogenic genes. J Lipid Res. 2002; 43:1220-1235.
40. Shimano H. Sterol regulatory element-binding proteins 
(SREBPs): transcriptional regulators of lipid synthetic 
genes. Prog Lipid Res. 2001; 40:439-452.
41. Reed BD, Charos AE, Szekely AM, Weissman SM, 
Snyder M. Genome-wide occupancy of SREBP1 and its 
partners NFY and SP1 reveals novel functional roles and 
combinatorial regulation of distinct classes of genes. PLoS 
Genet. 2008; 4:e1000133.
42. Rodriguez L, Bartolome N, Ochoa B, Martinez MJ. 
Isolation and characterization of the rat SND p102 gene 
promoter: putative role for nuclear factor-Y in regulation 
of transcription. Ann N Y Acad Sci. 2006; 1091:282-295.
43. Rodriguez L, Ochoa B, Martinez MJ. NF-Y and Sp1 are 
involved in transcriptional regulation of rat SND p102 gene. 
Biochem Biophys Res Commun. 2007; 356:226-232.
Oncotarget108194www.impactjournals.com/oncotarget
44. Armengol S, Arretxe E, Rodriguez L, Ochoa B, Chico Y, 
Martinez MJ. NF-kappaB, Sp1 and NF-Y as transcriptional 
regulators of human SND1 gene. Biochimie. 2013; 
95:735-742.
45. Armengol S, Arretxe E, Enzunza L, Mula S, Ochoa B, 
Chico Y, Martinez MJ. The promoter of cell growth- and 
RNA protection-associated SND1 gene is activated by 
endoplasmic reticulum stress in human hepatoma cells. 
BMC Biochem. 2014; 15:25.
46. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier 
M, Klingenhoff A, Frisch M, Bayerlein M, Werner T. 
MatInspector and beyond: promoter analysis based on 
transcription factor binding sites. Bioinformatics. 2005; 
21:2933-2942.
47. Sandelin A, Alkema W, Engstrom P, Wasserman WW, 
Lenhard B. JASPAR: an open-access database for 
eukaryotic transcription factor binding profiles. Nucleic 
Acids Res. 2004; 32:D91-D94.
48. Diczfaluy U. On the formation and possible biological role 
of 25-hydroxycholesterol. Biochemie. 2013; 95:455-460.
49. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro 
JM, Shimomura I, Shan B, Brown MS, Goldstein JL, 
Mangelsdorf DJ. Regulation of mouse sterol regulatory 
element-binding protein-1c gene (SREBP-1c) by oxysterol 
receptors, LXRalpha and LXRbeta. Genes Dev. 2000; 
14:2819-2830.
50. Del Castillo-Olivares A, Gil G. Differential effects of sterol 
regulatory binding proteins 1 and 2 on sterol 12 alpha-
hydroxylase SREBP-2 suppresses the sterol 12 alpha-
hydroxylase promoter. J Biol Chem. 2002; 277:6750-6757.
51. Kotzka J, Muller-Wieland D, Roth G, Kremer L, Munck 
M, Schurmann S, Knebel B, Krone W. Sterol regulatory 
element binding proteins (SREBP)-1a and SREBP-2 are 
linked to the MAP-kinase cascade. J Lipid Res. 2000; 
41:99-108.
52. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, 
Park O, Luo Z, Lefai E, Shyy JY, Gao B, Wierzbicki 
M, Verbeuren TJ, et al. AMPK phosphorylates and 
inhibits SREBP activity to attenuate hepatic steatosis and 
atherosclerosis in diet-induced insulin-resistant mice. Cell 
Metab. 2011; 13:376-388.
53. Seo YK, Jeon TI, Chong HK, Biesinger J, Xie X, Osborne 
TF. Genome-wide localization of SREBP-2 in hepatic 
chromatin predicts a role in autophagy. Cell Metab. 2011; 
13:367-375.
54. Seo YK, Chong HK, Infante AM, Im SS, Xie X, Osborne 
TF. Genome-wide analysis of SREBP-1 binding in mouse 
liver chromatin reveals a preference for promoter proximal 
binding to a new motif. Proc Natl Acad Sci U S A. 2009; 
106:13765-13769.
55. Inoue J, Sato R, Maeda M. Multiple DNA elements for 
sterol regulatory element-binding protein and NF-Y 
are responsible for sterol-regulated transcription of the 
genes for human 3-hydroxy-3-methylglutaryl coenzyme 
A synthase and squalene synthase. J Biochem. 1998; 
123:1191-1198.
56. Jeon TI, Esquejo RM, Roqueta-Rivera M, Phelan PE, Moon 
YA, Govindarajan SS, Esau CC, Osborne TF. An SREBP-
responsive microRNA operon contributes to a regulatory 
loop for intracellular lipid homeostasis. Cell Metab. 2013; 
18:51-61.
57. Feng R, Dong L. Inhibitory effect of miR-184 on the 
potential of proliferation and invasion in human glioma and 
breast cancer cells in vitro. Int J Clin Exp Pathol. 2015; 
8:9376-9382.
58. Ma F, Song H, Guo B, Zhang Y, Zheng Y, Lin C, Wu Y, 
Guan G, Sha R, Zhou Q, Wang D, Zhou X, Li J, Qiu X. 
MiR-361-5p inhibits colorectal and gastric cancer growth 
and metastasis by targeting staphylococcal nuclease domain 
containing-1. Oncotarget. 2015; 6:17404-17416. https://doi.
org/10.18632/oncotarget.3744.
59. Delgado I, Fresnedo O, Iglesias A, Rueda Y, Syn WK, 
Zubiaga AM, Ochoa B. A role for transcription factor E2F2 
in hepatocyte proliferation and timely liver regeneration. 
Am J Physiol Gastrointest Liver Physiol. 2011; 
301:G20-G31.
